TNF and myeloid sarcoma: The IDF eventually recommends other criteria to diagnose MS, such as increased levels of circulating inflammatory and/or thrombotic markers (CRP, SAA, TNF-α, IL-6, and PAI) or reduced levels of anti-inflammatory molecules, such as adiponectin.